RESMED INC (RMD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RMD

RMD - RESMED INC

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.37
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

ResMed is the global market leader in providing devices for the treatment of sleep apnoea and chronic pulmonary disease. Formed in Australia in 1989 the company listed on the ASX in 1999 and is also listed on the NYSE. ResMed's head office is in San Diego, California.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$30.50

14 Sep
2026

0.190

OPEN

$30.40

0.63%

HIGH

$30.63

753,022

LOW

$30.40

TARGET
$38.875 27.5% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . SHG . SLD . SOM . TRJ .
FNARENA'S MARKET CONSENSUS FORECASTS
RMD: 1
Title FY27
Forecast		 FY28
Forecast
EPS (cps) 176.2 xxx
DPS (cps) 38.9 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 17.8 xxx
Dividend Yield 1.2% xxx
Div Pay Ratio(%) 22.1% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.47%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.07

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 19/08 - (franking ex-div 6.55c)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx154.5
DPS All xxxxxxxxxxxxxxx35.2
Sales/Revenue xxxxxxxxxxxxxxx8,343.1 M
Book Value Per Share xxxxxxxxxxxxxxx659.0
Net Operating Cash Flow xxxxxxxxxxxxxxx2,664.9 M
Net Profit Margin xxxxxxxxxxxxxxx26.94 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx24.16 %
Return on Invested Capital xxxxxxxxxxxxxxx21.80 %
Return on Assets xxxxxxxxxxxxxxx17.69 %
Return on Equity xxxxxxxxxxxxxxx24.16 %
Return on Total Capital xxxxxxxxxxxxxxx26.89 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx1,918.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx417 M
Long Term Debt xxxxxxxxxxxxxxx775 M
Total Debt xxxxxxxxxxxxxxx1,192 M
Goodwill - Gross xxxxxxxxxxxxxxx4,200 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx2,126 M
Price To Book Value xxxxxxxxxxxxxxx4.38

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx261.5 M
Capex % of Sales xxxxxxxxxxxxxxx3.13 %
Cost of Goods Sold xxxxxxxxxxxxxxx3,316 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx2,189 M
Research & Development xxxxxxxxxxxxxxx558 M
Investments - Total xxxxxxxxxxxxxxx227 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.7

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

10/08/2026

1

Outperform

$46.80

53.44%

ResMed's June Q was mixed, Macquarie suggests, with revenue and gross profit in line, but gross margin -45bps below consensus, while higher hedge benefits pulled net profit 2% ahead.

Rest-of-world sales have outperformed for the third consecutive quarter with devices 3% ahead of consensus, and masks/accessories 4% ahead. This balanced an in-line result from Americas and slightly softer Residential Care Software performance.

Stripping out Astral impacts, June Q sleep devices rose 8% for Americas and 13% for RoW, above market growth at mid-single digit.

Near-term ventilator impacts aside, the core sleep business remains strong, Macquarie notes, with management confident in medium-term revenue and earnings growth, supported by year on year double-digit gross margin expansion and in spite of GLP-1 fears. 

Target increases to $46.80 from $46.60, Outperform retained.

FORECAST
Macquarie forecasts a full year FY27 dividend of 38.67 cents and EPS of 175.99 cents.
Macquarie forecasts a full year FY28 dividend of 40.41 cents and EPS of 186.99 cents.

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

22/07/2026

1

Buy

$40.00

31.15%

Canaccord Genuity maintains its Buy rating for ResMed with its target price lowered to $40.00 from $44.50 following adjustments for the MatrixCare divestment and the Noctrix acquisition.

Commentary states the divestment of MatrixCare for US$490m reflects ongoing challenges in delivering connected care cost-savings across post-acute settings.

The US$340m acquisition of Noctrix introduces the FDA-authorised Nidra platform targeting Restless Leg Syndrome, adding an estimated US$30m in FY27 revenue while lifting near-term operating expenses.

The analyst notes non-GAAP earnings per share for FY26 are projected at US$11.07, representing 15.8% growth over the prior year.

Despite competitive overhangs and emerging alternative therapies, Canaccord maintains current valuation multiples near decade lows offer attractive long-term entry points supported by core CPAP demand.
Access Extra Coverage Research History >

RMD STOCK CHART

FNArena News on RMD

1
Rudi’s View: Australia Remains Outside The AI Party

Sep 09 2026 - Rudi's View
2
August 2026 Results – The Wrap

Sep 08 2026 - Feature Stories
3
Rudi’s View: Resources, Healthcare & Best Buys

Sep 03 2026 - Rudi's View
4
Rudi’s View: August Delivers Soft Guidance, Higher Dividends

Aug 26 2026 - Rudi's View
5
Rudi’s View: Beats, Misses And Early AI Signals

Aug 19 2026 - Rudi's View

Latest Medical Equipment & Devices News

1
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
2
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
3
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
4
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
5
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
6
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
7
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
8
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
9
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
10
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals